Payne Fletcher 4

What Happened

• Payne Fletcher, former Senior VP and CFO of Aptose Biosciences (APTO), recorded dispositions on 2026-06-30 related to the company’s acquisition by a Hammi Pharmaceuticals subsidiary. He disposed of 1,255,244 total interests: 244 common shares sold to the issuer for $1.72 each (222 shares = $382; 22 shares = $38) and 1,255,000 derivative interests (options) reported as disposed at $0.00. Footnotes indicate the disposition was pursuant to a board/shareholder/court-approved business arrangement under which the buyer paid C$2.41 per share (converted at C$1.40 = US$1.00 to US$1.72).

Key Details

• Transaction date: 2026-06-30; reported filed 2026-07-01 (timely filing).
• Prices: C$2.41 per share (conversion used: C$1.40 = US$1.00) → US$1.72 reported per common-share disposition.
• Specifics: 222 shares @ $1.72 = $382; 22 shares @ $1.72 = $38; 55,000 / 200,000 / 1,000,000 derivative interests disposed @ $0.00 (listed as derivative dispositions).
• Total interests disposed: 1,255,244 (244 common shares + 1,255,000 options/derivatives); total cash shown on Form 4 ≈ $420.
• Footnotes: F1—dispositions pursuant to the Hammi acquisition at C$2.41/share; F2—USD conversion; F3—original option vesting schedule noted. Remark: option counts and exercise prices were adjusted for prior reverse splits.
• Shares owned after the transaction: not specified in the provided filing details.

Context

• These derivative dispositions appear tied to the corporate acquisition—options and outstanding interests were surrendered/settled under the transaction terms (hence $0 shown on some derivative lines). This is a disposition related to a change-of-control transaction, not an open-market sale or voluntary trading plan. As always, such filings are factual records of transfers; they do not by themselves indicate the insider’s personal view of the business’s future.